Specifically, the USPTO added human serotonin receptors 5HT2A and 5HT2C to the covered molecular targets, broadening the panel's use to a wider range of neuropsychiatric targets and conditions with an underlying autoimmune origin.
Research has increasingly pointed to a relationship between infection-triggered inflammatory attacks on the brain and neuropsychiatric conditions.
Results of the Cunningham Panel assist physicians in determining the likelihood that a patient's neuropsychiatric symptoms are due to an infection-triggered autoimmune response, rather than a primary psychiatric disorder.
Moleculera Labs is a privately-held autoimmune neurobiology company whose objective is to discover and deliver advanced testing services for children and adults suffering from treatable autoimmune central nervous system disorders.
The company's initial offering is the Cunningham Panel, a set of tests aimed at assisting clinicians in the diagnosis of PANDAS and PANS, conditions associated with motor tics, obsessive compulsive disorder, and sometimes autism spectrum disorders, that researchers believe to be caused by an autoimmune response triggered by common infections.
Moleculera Labs is a technology spin-out from the University of Oklahoma and operates a full CLIA (Clinical Laboratory Improvement Amendment) and COLA (Commission on Laboratory Accreditation) certified clinical laboratory in Oklahoma City where it performs the Cunningham Panel for physicians and clinicians throughout the United States and globally.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials